GUIDE-IT 试验中射血分数降低心力衰竭患者指南导向药物治疗优化限制的二次分析
该二次分析基于 GUIDE-IT 随机临床试验(美国及加拿大 45 个中心,894 例射血分数≤40% 的心衰患者),评估 NT-proBNP 引导治疗对比常规护理对 GDMT 优化的影响及未调整药物的原因。结果显示仅 15.5% 患者在 6 个月达到最佳 GDMT,常见未调整原因为「临床稳定」和「已达最大耐受剂量」,提示治疗惰性或目标不现实。
要点
- 仅 15.5% 患者在 6 个月达到最佳 GDMT,较基线 8.9% 有提升但组间无差异。
- 未调整药物最常见原因为「临床稳定」和「已达最大耐受剂量」。
- 较高剂量 β 受体阻滞剂与复合终点及全因死亡风险降低相关。
核心结论
- 尽管采用方案驱动方法,许多 GUIDE-IT 患者未接受药物调整且未达到最佳 GDMT,包括 NT-proBNP 已知升高的患者。
- GUIDE-IT 未产生治疗获益可能源于临床实践中的治疗惰性,或当前 GDMT 目标不现实。
研究设计与样本
- GUIDE-IT 为随机临床试验,在美国和加拿大 45 个中心于 2013 年 1 月 16 日至 2016 年 9 月 20 日进行。
- 共 894 例射血分数≤40% 的心衰患者随机接受 NT-proBNP 引导治疗(目标 NT-proBNP <1000 pg/mL)或常规护理。
- 本二次分析纳入 838 例可分析患者(566 例男性,67.5%;中位年龄 62.0 岁),分析 24 个月内 6223 次访视。
主要发现
- 在 5218 次合格访视中,2847 次(54.6%)进行了心衰药物调整,涉及 862 例患者(96.4%)。
- 多数调整发生在前 6 个月内,主要在前 6 周内。
- 未调整最常见原因为「临床稳定」和「已达最大耐受剂量」。
- 6 个月时仅 130 例(15.5%)达到最佳 GDMT(β 受体阻滞剂或 ACEI/ARB 目标剂量≥50% 或任何剂量 MRA),较基线(79/891,8.9%)增加但治疗组间无差异。
关键数值与推荐
- 最佳 GDMT 定义:β 受体阻滞剂或 ACEI/ARB 目标剂量≥50% 或任何剂量 MRA。
- NT-proBNP 引导治疗目标:抑制 NT-proBNP 浓度至 <1000 pg/mL。
临床怎么用
- 临床中应关注治疗惰性,即使患者临床稳定也应评估 GDMT 滴定机会。
- 对 NT-proBNP 升高患者应积极调整药物,而非仅因「临床稳定」而不调整。
- β 受体阻滞剂、ACEI 和 ARB 较高剂量与死亡风险降低相关,支持在可耐受范围内上调剂量。
局限性
- 为二次分析,结果可能受未测量混杂因素影响。
- 仅纳入 GUIDE-IT 试验人群,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite evidence that guideline-directed medical therapy (GDMT) improves outcomes in patients with heart failure (HF) and reduced ejection fraction, many patients are undertreated. The Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT) trial tested whether a strategy of using target concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) to guide optimization of GDMT could improve outcomes. OBJECTIVE: To examine medical therapy for HF in GUIDE-IT and potential reasons why the intervention did not produce improvements in medical therapy. DESIGN, SETTING, AND PARTICIPANTS: GUIDE-IT, a randomized clinical trial performed at 45 sites in the United States and Canada, was conducted from January 16, 2013, to September 20, 2016. A total of 894 patients with HF and reduced ejection fraction (≤40%) were randomized to NT-proBNP-guided treatment with a goal to suppress NT-proBNP concentrations to less than 1000 pg/mL vs usual care. This secondary analysis examined the medical therapy titration and reasons why the intervention did not produce improvements in care and outcomes. Data were analyzed March 27 to June 28, 2019. MAIN OUTCOMES AND MEASURES: For each encounter, medication titrations were captured. A reason was requested if a modification was not made. A Cox proportional hazards regression model was used to assess the independent association of drug class with outcomes. RESULTS: Among the 838 patients available for analysis (566 men [67.5%]; median age, 62.0 years), 6223 visits occurred during 24 months. Adjustments of HF medication were made during 2847 of 5218 qualified visits (54.6%) (all usual care visits and all guided care visits with NT-proBNP level ≥1000 pg/mL) in 862 patients (96.4%). Most adjustments occurred within the first 6 months, primarily within the first 6 weeks. The most common reasons for not adjusting were "clinically stable" and "already at maximally tolerated therapy." Only 130 patients (15.5%) achieved optimal GDMT (≥50% of the target dose of β-blockers or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or any dose of mineralocorticoid antagonists) at 6 months, an increase from the baseline (79 of 891 [8.9%]) but not different by treatment arm. Higher doses of β-blockers were associated with reduced risk of the composite outcome of HF hospitalization and cardiovascular death (hazard ratio [HR], 0.98; 95% CI, 0.97-1.00; P = .008) and of all-cause death (HR, 0.97; 95% CI, 0.95-0.99; P = .01). Higher doses of angiotensin-converting enzyme inhibitors (HR, 0.84; 95% CI, 0.75-0.93; P < .001) and angiotensin receptor blockers (HR, 0.84; 95% CI, 0.71-0.99; P = .04) were associated with reduced risk of all-cause death. Increasing doses of mineralocorticoid antagonists did not appear to be associated with improved outcomes. CONCLUSIONS AND RELEVANCE: Despite a protocol-driven approach, many patients in GUIDE-IT did not receive medication adjustments and did not achieve optimal GDMT, including those with known elevated NT-proBNP concentrations. These results suggest that opportunities exist to titrate medications for maximal benefit in HF. GUIDE-IT may have failed to achieve treatment benefit because of therapeutic inertia in clinical practice, or current GDMT goals may be unrealistic. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01685840.
引用
- Fiuzat M, Ezekowitz J, Alemayehu W, et al. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2020. PMID: 32319999. doi:10.1001/jamacardio.2020.0640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。